-
Astellas Pharma Executive Arrested in China on Spying Allegations
•
A Japanese national and executive at the Chinese division of Tokyo-based Astellas Pharma Inc. (TYO: 4503) has been arrested by China’s state security bureau on suspicion of espionage. The specific details of the alleged charges have not been disclosed to the public. The arrest was initially reported by Japanese media…
-
China’s NHSA Introduces Tiered Pricing for COVID-19 Therapies: A, B, and C Categories
•
The National Healthcare Security Administration (NHSA) has issued a Notification concerning the improvement of the pricing mechanism and the implementation of classified management for COVID-19 therapeutic drugs. This move signifies a new approach to categorizing COVID-19 drugs into A, B, and C classes outside the National Reimbursement Drug List (NRDL).…
-
Shanghai Pharmaceuticals’ SPH4336 Earns Orphan Drug Status for Liposarcoma Treatment
•
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its drug candidate, SPH4336. This designation is for the potential treatment of liposarcoma, a rare form of cancer.…
-
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
•
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV) with Taiwan-headquartered Rxilient Biotech to develop and commercialize its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), across Southeast Asia. The agreement covers key territories including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.…
-
Novartis’ Kisqali Demonstrates Improved iDFS in Phase III NATALEE Study for Early Breast Cancer
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III NATALEE study has achieved its primary endpoint of invasive disease-free survival (iDFS). The study assessed the efficacy of Kisqali (ribociclib) in combination with endocrine therapy (ET) for hormone receptor-positive/human epidermal growth factor receptor 2 negative…
-
Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study
•
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced that its IL-4Rα monoclonal antibody (mAb) drug candidate, CM310, has successfully reached its primary endpoints in a confirmatory Phase III clinical study for the treatment of moderate to severe atopic dermatitis (AD). Phase III Study…
-
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
•
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based in China, has joined forces with Venus Medtech (Hangzhou) Inc., another prominent player in the medical field (HKG: 2500), to announce the establishment of a partnership fund. Each company is contributing RMB 125 million (USD…
-
AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030
•
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the UK-based pharmaceutical giant is planning to triple its investment in research and development in China over the coming months. This strategic move aims to increase the number of innovative drugs entering the Chinese market, as…
